Takeda Pharmaceutical Co Ltd ADR (TAK) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Takeda Pharmaceutical Co Ltd ADR stock (TAK) is currently trading at $18.29. Takeda Pharmaceutical Co Ltd ADR PE ratio is 82.00. Takeda Pharmaceutical Co Ltd ADR PS ratio (Price-to-Sales) is 0.01. Analyst consensus price target for TAK is $19.53. WallStSmart rates TAK as Hold.
- TAK PE ratio analysis and historical PE chart
- TAK PS ratio (Price-to-Sales) history and trend
- TAK intrinsic value — DCF, Graham Number, EPV models
- TAK stock price prediction 2025 2026 2027 2028 2029 2030
- TAK fair value vs current price
- TAK insider transactions and insider buying
- Is TAK undervalued or overvalued?
- Takeda Pharmaceutical Co Ltd ADR financial analysis — revenue, earnings, cash flow
- TAK Piotroski F-Score and Altman Z-Score
- TAK analyst price target and Smart Rating
Takeda Pharmaceutical Co Ltd ADR
📊 No data available
Try selecting a different time range
TAK Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Takeda Pharmaceutical Co Ltd ADR (TAK)
TAK trades 77% above its Graham fair value of $10.30, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Takeda Pharmaceutical Co Ltd ADR (TAK) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, price/sales. Concerns around return on equity and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Takeda Pharmaceutical Co Ltd ADR (TAK) Key Strengths (5)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Earnings per share surging 330.20% year-over-year
Large-cap company with substantial market presence
Trading at 1.18x book value, attractively priced
Supporting Valuation Data
Takeda Pharmaceutical Co Ltd ADR (TAK) Areas to Watch (5)
Very low returns on shareholder equity
Revenue growing slowly at 4.20% annually
Very thin margins, barely profitable
Very low institutional interest at 2.72%
Thin operating margins with cost pressures present
Supporting Valuation Data
Takeda Pharmaceutical Co Ltd ADR (TAK) Detailed Analysis Report
Overall Assessment
This company scores 60/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.4/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, EPS Growth. Valuation metrics including PEG Ratio (0.39), Price/Sales (0.01), Price/Book (1.18) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 330.20%.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Profit Margin. Growth concerns include Revenue Growth at 4.20%, which may limit upside. Profitability pressure is visible in Return on Equity at 1.50%, Operating Margin at 10.80%, Profit Margin at 2.53%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 1.50% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 4.20% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Sales) and negatives (Return on Equity, Revenue Growth). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TAK Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TAK's Price-to-Sales ratio of 0.01x trades at a deep discount to its historical average of 0.03x (21th percentile). The current valuation is 79% below its historical high of 0.06x set in Apr 2013, and 28% above its historical low of 0.01x in Dec 2024. Over the past 12 months, the PS ratio has expanded from ~0.0x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Takeda Pharmaceutical Co Ltd ADR (TAK) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Takeda Pharmaceutical Co Ltd ADR is a strong growth company balancing expansion with improving profitability. Revenue reached 4.5T with 420% growth year-over-year. Profit margins are strong at 253.0%, reflecting pricing power and operational efficiency.
Key Findings
Revenue growing at 420% YoY, reaching 4.5T. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
ROE of 150.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
What to Watch Next
Growth sustainability: can Takeda Pharmaceutical Co Ltd ADR maintain 420%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 82.0x. Any growth miss could trigger a sharp correction.
Dividend sustainability with a current yield of 3.7%. Watch payout ratio and free cash flow coverage.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Takeda Pharmaceutical Co Ltd ADR.
Bottom Line
Takeda Pharmaceutical Co Ltd ADR offers an attractive blend of growth (420% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Takeda Pharmaceutical Co Ltd ADR(TAK)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.